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Abstract
Phenylalanine mustard (PAM) and nitrogen mustard (HN2) are bifunctional
alkylating agants which covalently crosslinkDNA. Their crosslinking ability forms the
basis of their usefulness as anti-cancer drugs since crosslinkedDNA cannot replicate and
thus the cancers cells cannot reproduce. Despite apparent similarities, the two drugs are
known to have important differences. PAM is more effective against cancer and has fewer
side effects. In reactions with cell cultures, PAM produces crosslinks more slowly, but the
crosslinks are more persistant The experiments reported here offer kinetic explanations for
the differences.
In vitro time-dependent crosslinking reaction profiles for HN2 and PAM produced
using an alkaline ethidium bromide assay for crosslinkedDNA are virtually identical to
what has been reported in vivo using an alkaline elution method. This suggests that the
differences between the two drugs can be explained by purely chemical processes. In
particular, the difference in the persistence of PAM andHN2 crosslinks in vivo does not
require differences in the rate of enzymatic repair of the two types of lesions since loss of
crosslinks in vitro follows the same schedule.
A novel modification of the ethidium bromide assay reveals that PAM andHN2 have
similar solution stabilities in neutral sodium phosphate buffer. This rules out the possibility
that the pharmocological differences between PAM andHN2 are attributable to differential
solution stabilities.
The dependence of the rate of the crosslinking reaction on drug concentration is linear
for both drugs. This confirms previous in vivo studies which suggested that the
crosslinking reaction is pseudo first order for drug concentration. The dependence of the
reaction rate on the temperature shows that PAM andHN2 have similar activation energies
for the crosslinking reaction but PAM has a less favorable steric factor as predicted based
on PAM's bulky phenylalanine portion.
The crosslinked products for PAM andHN2 were isolated and their rates of
decomposition were shown to be first order. PAM crosslinks have a longer half-life and a
larger portion ofPAM's crosslinks resist decay. These observations may be sufficient to
explain the differences between PAM's andHN2's reaction profiles in vivo and in vitro
andmay be responsible for PAM's greater therapeutic value. A model is proposed to
account for PAM's longer half-life and greater fraction of decay-resistant crosslinks.
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1Introduction
Phenylalanine mustard (PAM) and nitrogen mustard (HN2) (structures are shown in
Figure 1-1) are anti-cancer drugs which owe their effectiveness to their ability to covalently
crosslinkDNA. CrosslinkedDNA is unable to replicate and a cell so affected cannot
reproduce and eventually dies. In the case of cancer cells, death is the desired effect, but
many of the side effects of these and other anti-cancer drugs stem from their effects on
normal body cells which have short cell cycles.
Although PAM andHN2 have been widely used for many years, there are many
unanswered questions about theirmechanisms of action. In particular, despite apparently
similar reactions with DNA, PAM is more effective against cancer and less likely to
produce side effects. Understanding the chemical basis for PAM's effectiveness could lead
to the design of related drugs with even greater effectiveness and/or fewer side effects.
The goal of this reseach was to use the ethidium bromide assay for denaturation-
resistantDNA to explore various aspects of the PAM-DNA andHN2-DNA reactions in
vitro . In particular , we sought rate constants, activation energies, and steric factors for
the reactions of the drugs with DNA and for the loss of crosslinks from DNA. These
values could then be compared with similar values obtained in vivo so that the effects of
cellular processes on reaction profiles might be evaluated more rationally. The values can
also be compared for the two drugs in an attempt to explain their differences in clinical
effectiveness. Furthermore, our data is used to evaluate models forDNA crosslinking by
PAM and HN2.
Each chapter of this report deals with a variation of the ethidium bromide assay
method which provides a particular type of information. General experimental procedures
will be discussed in the next section. Introductorymaterial and modifications of the
experimental method are included in each chapter.
CH2CH2-C1
H3C-N'
VCH2CH2-Q
Nitrogen Mustard, HN2
[OOC / \ (NCH-CH2 (O ) N'
HOOCK /~^ CH2CH2-C1
"CH2CH2-C1
PhenylalanineMustard, PAM
Figure 1-1: Structural Formulas for Nitrogen Mustards
General Experimental Methods
This sectionwill detail experimental methods that are common to all chapters.
Modifications of the basic procedures and any specialmethods will be discussed in the
chapters in which they were applied
Theory
Our primary tool for detecting and quantifying crosslinks is an ethidium bromide
assay developed by Lown (1979) based on Morgan's and Pulleyblank's (1974)
demonstration that ethidium bromide flouresence could be used to measure duplex DNA. It
depends upon features of ethidium bromide and ofDNA. The structure of ethidium
bromide is shown in Figure M-l. Ethidium bromide is capable of intercalating between
adjacent base pairs of duplex DNA, with about one molecule of ethidium bromide per two
bases pairs at saturation. In aqueous solution, ethidium bromide is weakly fluorescent, but
in the hydrophobic environment of duplex DNA base pairs, the fluorescence is enhanced
on the order of a hundred-fold. Thus ethidium bromide serves as an indicator for duplex
DNA.
The assay also depends upon differences between the behaviors of cross-linkedDNA
and non-crosslinkedDNA. Figure M-2, adapted from Lown , shows these differences.
Both DNAs will denature if heated under alkaline conditions (pH>l 1). An interstrand
crosslink holds the separated strands of crosslinkedDNA in register, while the strands of
non-crosslinkedDNA randomly disperse in solution. Upon cooling, crosslinkedDNA
regains duplex form while non-crosslinked DNA remains single-stranded. Crosslinked
DNA will enhance the fluorescence of ethidium bromide, despite having been through
denaturing conditions, whereas non-crosslinked DNA will not
Thus the extent ofDNA interstrand crosslinking caused by an anticancer drug can be
measured as a function of time by adding the drug/DNA mixture to an alkaline solution of
ethidium bromide, heat denaturing the sample, cooling it, andmeasuring the fluorescence.
NH,
Figure M-l Structure of Ethidium Bromide
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Figure M-2 Schematic for Ethidium Bromide Assay for Crosslinked DNA
Solutions Preparations
Phosphate Buffers
20 mM stock solutions ofNa3P04, Na2HP04, and NaH2P04 were prepared. A
working 20 mM sodium phosphate pH 7 bufferwith 0.15 M NaCI was prepared by
mixing appropriate quantities of the NaH2P04 and Na2HP04 stock solutions plus NaCI. A
working 20 mM sodium phosphate pH 1 1.4 bufferwas prepared from the Na3P04 and
Na2HP04 stocks. All buffer solutions were stored in 1 1. clear plastic bottles. Sources of
materials were as follows: Na3P04-12 H2O, molecular weight equals 380.12, was
J.T.Baker Lot #64612. Na2HP04 (anhydrous), molecular weight equals 141.96, was
Mallinckrodt Lot # 7859 KBTA. NaH2P04 H20, molecular weight equals 137.99, was
J.T. BakerLot # A14094. NaCI, formula weight equals 58.44, was Mallincrodt Lot
KHRK.
Ethidium Bromide Assay Solution
The standard assay solution was prepared to be 0.2 mM EDTA and 1.27 U.M
ethidium bromide in 20mM sodium phosphate bufferwith pH of 1 1.4. EDTA-3H20
(sodium ethylenediaminetetraacetate) has amolecularweight of 372.24 and was FisherLot
# 721 130. Ethidium bromide (2,7-dianimo-10-ethyl-9-phenyl-phenanthridinium bromide)
has amolecular weight of 394.3, a molar absorption coefficient of 5450M"l cm"! at 480
nm, and was Sigma Lot #32F-0819. For ease of handling, a concentrated EB stock was
made by dissolving about 10 mg. EB in 10 ml pH 7, 20mM sodium phosphate buffer.
The exact concentration ofEB in this solution was calculated by measuring the absorbance
at 480 nm and applying Beer's Law, c=A/eb where c is the concentration (M), A is the
measured absorbance, e is the molar absorptivity (M*1 cm'1), and b is the pathlength of
the sample (cm). Appropriate quantities of concentrated EB stock andEDTA were then be
added to pH 1 1.4 sodium phosphate buffer. Because EB is degraded by light the assay
solution was stored in brown plastic bottles under refrigeration.
Ethidium Bromide Fluorescence Standard
The EB concentrated stock solution was diluted with pH 7, 20 mM sodium phosphate
buffer to give a solution with fluorescence properties similar to those of a typical
DNA/assay sample. The goal was tomatch the emission spectra from 560 to 680 nm
(excitation X=540). This required a fluorescence standardwhich was about 17 |iM EB.
Each time a new batch ofEB fluorescence standard was prepared, its fluorescence was
referenced to the old batch so that data collected at various times would be comparable.
The EB fluorescence standard reference solution was stored refrigerated in brown plastic
bottles to prevent photodegradation. Use of the EB standard is described under fluorimeter
parameters.
DNA Solutions
The DNA used formost experiments was ultrapure calf thymus DNA, molecular
weight = 9.7 x 10^, Lot # 28F-6745 from Sigma. It was supplied in vials containing 5
units ofDNA. A unit is the amount ofDNA which will yield an A26O of 1 .0 when
dissolved in 1.0 ml. of buffer. The DNA was stored in the freezer and was allowed to
equilibrate to room temperature overnight before use. Itwas desired that the reaction
mixture's DNA content give A26O = 1, so the DNA stock solution was to be A26O = 2, or
0.32 mM DNA-phosphate, to allow for dilution by an equal volume of drug solution at the
initiation of a reaction. 20 mMpH 7 sodium phosphate buffer with 0.15M NaCI was used
to dissolve the DNA. The bufferwas added gradually with intermediate checks ofA26O to
ensure that the DNA was not overdiluted. The A26O = 2NA solution was partitioned into
400 uJ quantities in 0.5 ml plastic centrifuge tubes in which itwas frozen. FrozenDNA
solutions were allowed to equilibrate to room temperature for at least two hours before use.
PAM and HN2 Solutions
Melphalan (also called phenylalanine mustard, sarcosylin, or PAM) is 4-[bis(2-
chloroethyl)amino]-L-phenylalanine. PAM, molecularweight equals 305.2, was obtained
from Sigma, Lot 38F-0693. Mechlorethamine (also called nitrogen mustard orHN2) is 2-
chloro-N-[2-chloroethyl]-N-methyl ethanamine HCL HN2HC1, molecular weight equals
192.5, was a gift from James Henkel of the Department ofPharmacology of the University
ofConnecticut at Storrs. The crystalline drugs were stored in a desiccator at 40 F. Due
to the limited solution stabilities of the nitrogen mustards, all solutions were prepared
immediately prior to use. A small quantity of the drug was weighed in a tared glass ampule
using aMettlar balance. The following calculation was used to determine the volume (ml)
of buffer needed to dissolve the drug and to dilute it to the appropriate concentration: mg.
of drug x 1/molecularweight of drug x 1/desired concentration (mM) x 1000. Note that the
desired concentration for the drug solution was always twice the concentration desired in
the reaction to allow for the 1 to 2 dilution upon mixing the DNA and drug solutions to
initiate the reaction. This quantity of pH 7 20 mM phosphate bufferwith 0. 15 M NaCL
was measured into a clean oven-dried 40 ml. glass vial using a Kimax disposable 10 ml
pipette. The bufferwas allowed equilibrate to the desired reaction temperature for at least
20minutes, at which time the ampule containing the drug was added to the buffer and the
vial was agitated using a vortexmixer. After a predilution time, generally 20 minutes for
PAM and 10 minutes forHN2, a small volume of the drug solution was added to an equal
volume ofDNA solution to initiate the reaction, diluting the drug by half to the target
concentration.
Fluorimeter Parameters
All fluorescence measurements were taken on a Perhin-Elmer LS-5B Luminescence
Spectrometer. Following experiments to determine the parameters which would give the
highest signal-to-noise ratio, these instrument settings were used chosen as standard:
Excitation slit setting was 5 and no filterwas used. Emission slit setting was 20 and a red
filterwas used. Speed was set at 120 and response was set at 4. A 500 mL sample in a
cuvette with a 1 cm. path length was excited at 525 nanometers, and fluorescence was
measured at 600 nanometers. The instrument was calibrated by setting the fluorescence of
an ethidium bromide fluorescence standard sample in cuvette holder #2 to a specified
value. The fluorescences of the experimental samples were measured in cuvette holder #4
Denaturation Parameters
Samples were generally denatured in groups of 12 in a plastic holder in a 104 C sand
bath for 2 minutes, then quenched in a0 C ice bath for 5 minutes. Each group of 12
contained at least one control sample, prepared by adding 20 \iL ofDNA solution (A260=l)
to 1000 uL of ethidium bromide assay solution. The A260=l DNA solution was prepared
by diluting the stock A260=2 DNA solution with an equal volume of 20 mM pH 7 sodium
phosphate buffer. After temperature equilibration in a room temperature water bath for at
least 15 minutes, the samples were centrifuged for 2 minutes to avoid transferring any solid
particles to the fluorescence cuvette. Denatured fluorescences were then measured.
Calculation of Percent Crosslinking
Using amicropipette, 20 |il aliquots were taken from the DNA-drug reaction mixture
for determination of percent crosslinking. Each aliquot was added to a labelled plastic
microcentrifuge tube containing 1000 ui of assay solution which had equilabrated to room
temperature for at least two hours. The fluorescence of the solution was measured as
described under fluorimeter parameters and this value was recorded as Fioo- Then the
solution was subjected to the denaturation protocol followed by a second fluorescence
measurement, recorded as Fd- Fioo and FD were also measured for control samples which
were simply 20 ui aliquots of A260=1 NA solution in 1000 ui of assay solution. Fioo
values of controls served as informal quality control checks for the assay and fluorimeter
while Fd for the controls represents the background fluorescence of the assay with no
crosslinkedDNA. Thus the following formula was used to calculate the percent
crosslinking in a sample:
% crosslinking = (Fd sample " Fd control) / (FlOO sample " Fd control) x 100%
10
Percent crosslinking must be interpreted as the percent ofDNA molecules having at
least one crosslink since one crosslink is sufficient to allow the entire molecule to return to
duplex form after alkaline heat denaturation.
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Chapter 1: Reaction Profiles
Introduction
Nitrogenmustard has been used as an anticancer agent for 44 years and one of the
nitrosoureas has been in use for 28 years. Various researchers have tackled questions
about the mechanisms of action of these drugs. Early work by Kohn, Spears, and Doty
(1966) using density gradient centrifugation showed that the lethal lesion caused by
nitrogenmustard is likely a DNA interstrand crosslink. The evidence was that only
bifunctional drugs were able to prevent irreversible denaturation of theDNA.
The next step was to study the rates of formation and loss ofDNA crosslinks in vivo
for the various drugs. The alkaline elution technique used by Ross, Ewig, and Kohn
1978) for quantifying DNA crosslinking depends on crosslinkedDNA being retained on a
filter while non-crosslinked DNA passes through. They foundmajor differences between
the kinetics of two of the N-mustards. PAM crosslinked more slowly, but its crosslinks
were more persistent The interpretation was that PAM was more effective because its
crosslinks persist longer. These results are shown in Figure 1-1.
Hansson et al (1987) later used a refined technique which could distinguish between
DNA interstrand crosslinks and DNA-protein crosslinks. Their crosslinking reaction
profiles were quite similar to Ross's and are shown in Figure 1-2. They found that area
under the DNA interstrand crosslinking curve correlated highly with cytotoxicity. Thus
PAM, having the greater area under the curve, would be the more effective anticancer drug.
They also suggested that the differences in persistence ofPAM- andHN2- produced
crosslinks was due to differential enzymatic repair of the lesions.
12
HOURS POST-TREATMENT
Chart 5. Changes In cross-linking following cell exposure to either HN2
(0.20 tiM) or melphalan (15 ^m) for 0.5 hr. Cross-linking equivalents are
derived from the calibration line in Chart 3. O. HN2-treated cells; A. cells
treated with melphalan. Cells on ice received 600 R just prior to elution.
Figure 1-1 Chart 5 from Ross et al ( 1978) showing reaction profiles for HN2 and PAM
with L1210 cells.
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Figure 1-2 Figure 3b from Hansson et al (1987) showing reaction profiles for PAM and
HN2 with RPMI 8322 cells.
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Prior to invoking unproven cellular processes to explain the differences between
PAM andHN2 crosslinking, it would be useful to know their intrinsic chemical
differences. Chapter 1 contains time-dependent reaction profiles forPAM and HN2 with
purified cell-freeDNA. These profiles show the intrinsic differences between the reactions
ofPAM and HN2. Now that the intrinsic differences are known, amore rational search for
explanations of the differences can be initiated. The purely chemical time-dependent
reaction profiles are compared with the cellular time-dependent profiles. So far as the two
types of reaction profiles coincide, intrinsic chemical properties ofPAM andHN2 probably
account for the shapes of both the cellular and the acellular profiles. These intrinsic
chemical properties will be explored in succeeding chapters. Where the two types of
reaction profiles differ, cellular processes probably cause the differences. Various cellular
processes which may affect the time-dependent reaction profiles are discussed.
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Procedures
DNA-Drug Reactions
Standard procedures were used to prepare all solutions. Profile reactions were
carried out at 37C. Once a reaction was initiated, 20 uL aliquots were removed at set
times using amicropipette. Each aliquotwas added to 1000 pi of ethidium bromide assay
in a plastic microcentrifuge tube. Generally samples were refrigerated overnight so that all
fluorescence readings could be taken together after suitable equilibration to room
temperature. Controls were prepared using standard procedures. Percent crosslinking was
calculated for each sample and plots were prepared ofpercent crosslinking as a function of
time.
16
Results
PAM
Figure 1-3 shows a reaction profile for PAM. Because of the scarcity and scatter of
the data at the time ofmaximum crosslinking, we cannot be precise in stating the time of
maximum crosslinking for PAM. However, it is evident that PAM achievedmaximum
crosslinking of about 80% sometime between 200 and 300 minutes (3.3 to 5 hours) into
the reaction. Technical problems prevented acquiringmore data at later times; however, it
can be seen that the apparent half life of crosslinks is around 20 hours. A similar
experiment gave the apparent half life as 39 hours with a maximum of 88% crosslinking
about 3 hours into the reaction. (J. Yeh, unpublished data)
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DNA Time-Dependent Crosslinking Profile for PAM
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Figure 1-3 PAM Time-Dependent DNA Crosslinking Reaction Profile: [Drug]/[P]=0.35,
37C, MK1-54
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HN2
Figures 1-4 and 1-5 show reaction profiles forHN-2. In both cases, the maximum
crosslinking of about 82% was reached by 50 to 90 minutes. The apparent half life for loss
of crosslinks was about 400 minutes (6.7 hours).
19
DNA Time-Dependent Crosslinking Profile for HN2, Trial 1
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Figure 1-4 HN-2 Time-Dependent DNA Crosslinking Reaction Profile, Trial 1.
[Drug]/[P]=0.37 , 37 C, MK1-34
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DNA Time-Dependent Crosslinking Profile for HN2, Trial 2
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Figure 1-5 HN-2 Time-Dependent DNA Crosslinking Reaction Profile, Trial 2.
[Drug]/[P]=0.37, 37 C, MK1-128
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Discussion
Comparison of PAM and HN-2 Profiles
Comparison of the reaction profiles of PAM andHN-2 reveals both similarities and
differences. Both drugs reach a similarmaximum extent of crosslinking (80 to 88%), an
indication thatmaximum extent of crosslinking attainable is not the key factor in their
differences in clinical efficacy. The time required to achieve maximum crosslinking is very
different for the two drugs. HN-2 reaches its maximum in less than an hourwhile PAM
takes over three hours. HN-2 crosslinks are also lost much fasterwith an apparent half life
of about 6.7 hours in comparison to an apparent half life for PAM crosslinks of 20 to 40
hours.
Comparison of Experimental Data to the Literature
These results are quite similar to classic data generated by the alkaline elution method
whichmeasures a combination ofDNA interstrand andDNA-protein crosslinks in cells.
Ross, Ewig, and Kohn (1978) reported a crosslinking profile formouse leukemia L1210
cells exposed to HN-2 for 30 minutes which is virtually identical to ours for isolated calf
thymus DNA. The shape of their profile for PAM is similar to the ours with a slow rise to
maximum crosslinking and a very slow loss of crosslinking, but the times associated with
these events are somewhat different. They saw PAM reach a high level of crosslinking
after about 90 minutes and continue to rise slowly to a plateau where it remained at 6 to 12
hours compared with ourmaximum at about 3.3 to 5 hours. They thought that PAM's
slow on rate, in light ofPAM's instability in solution, might be explained by a 2-step
reaction of fastmonoalkylation followed by slow crosslinking. HN2 which reacts faster
would not require a slow second step, although the literature shows evidence for such a
time lag. Kohn, Spears, and Doty (1966) and Kohn and Green (1966) saw a delay
between treatmentwith HN2 and and attainment ofdenaturation resistance as measured by
CsCl density -gradient equilibrium ultracentrifugation following exposure to sodium
hydroxide or formamide. Our profiles also show a longer reaction time before maximum
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crosslinking is reached for PAM than forHN2, but the time we see formaximum
crosslinking with PAM is only 3.3 to 5 hours comparedwith their 6 to 12 hours. Thus our
profiles, in conjunction with the solution stability data presented in Chapter 2, do not
require a slow second step for PAM and suggest that some cellular process may be
responsible for the very slow crosslinking ofDNA by PAM in cells. Ross's group did not
report a half life for PAM crosslinks, but one of about 18 hours can be extracted from their
graph.
Hansson, Lewensohn, and Nilsson (1987) later refined the alkaline elution technique
to differentiate between DNA interstrand crosslinks andDNA-protein crosslinks. Their
results for interstrand crosslinking using a human melanoma cell line for the most part
paralleled both Ross's and ours. HN-2 producedmaximum crosslinking almost
immediately and lost it fairly quickly with a half life of 7.9 hours. PAM achieved
maximum crosslinking by 12 hours and lost the crosslinks very slowly with a half life of
12.9 hours. Besides the longer time formaximum crosslinking with PAM as discussed
above, another major difference between their data and ours is their finding that a given
concentration ofHN-2 gave amaximum extent of crosslinking about 13 times that ofPAM
at the same concentration. We did not see anything like this: equal concentrations ofPAM
andHN-2 gave essentially equal maximum extents of crosslinking though at different rates.
For purposes of comparison, key aspects of the reactions of PAM andHN2 with
DNA for Ross's, Hansson's, and our experiments are summarized in Tables 1-1 and 1-2.
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Ross etal
(L1210 cells)
Time needed to
achieve maximal
crosslinking
Apparent ti/2 for
loss of crosslinks
Table 1-1 Comparison of Profile Values for HN2
Hansson et al Kaminsky
(Human Melanoma CalfThymus DNA
cells)
1.5 hours 0.5 hour treatment 50 to 90 minutes
7 hours 7.9 hours 6.7 hours
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Ross et al
(L1210 cells)
Time needed to
achieve maximal
crosslinking
Apparent ti/2 for
loss of crosslinks
Maximum extent of
crosslinking
compared that
produced by HN2
Table 1-2 Comparison of Profile Values for PAM
Hansson et al
QHuman Melanoma
cells)
Kaminsky
CalfThymus DNA
Plateau at 6 to 12
hours
12 hours 3-5 hours
18 hours
(interpolated)
12.9 hours 20-39 hours
75 times greater
concentration of
PAM than HN2 gave
equal maximum
crosslinking.
For equal
concentrations, HN2
gave 13 times greater
crosslinking than
PAM.
Equal concentrations
ofPAMandHN2
gave equal maximum
crosslinking.
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It appears that purely chemical processes can account for the reaction ofHN2 with
DNA in cells while cellular processesmay have an influence on certain aspects ofPAM's
reaction with DNA in cells. In particular, cellular processes may delay the time and extent
ofmaximum crosslinking by PAM andmay hasten the loss ofPAM-induced crosslinks.
Cellular Processes Which Affect PAM's Rate and Extent of Crosslinking
Transport
PAM andHN2 have been found to enter the cell through different carrier systems.
HN2 has been shown to use the choline membrane carrier system in a number of cell lines
(Hakala, 1974) while evidence indicates that PAM enters the cell via the leucine transport
system. (Vistica, 1983) There would be no reason to expect that these different transport
systems would deliver the drugs into the cell at equal rates, so it is likely that the different
cell membrane transport systems contribute to the differentmaximum extents of
crosslinking ofPAM andHN2 in vivo despite their similar maximum extents of
crosslinking in isolatedDNA.
In addition to getting past the cell membrane, PAM andHN2 must penetrate the
nuclear membrane in order to reach and crosslinkDNA. There is evidence that nuclear
permeability to PAM contributes its effectiveness. Elliot and Ling (1981) measured the
uptake of radioactively-labelled PAM into the nuclei ofmelphalan-resistant Chinese hamster
ovary cells and found that the resistant strains had significantly less PAM in the nuclear
fraction than did the parent strain. The mechanism for this is not known, but differences
between the rates ofPAM andHN2 nuclear penetration could also contribute to their
differentmaximum extents of crosslinking in cells.
Influence ofEndogenous Thiols
Dorr (1987) used L-buthionine (S/R) sulfoximine to deplete endogenous thiols such
as glutathione in L-1210 mouse leukemia cells. He compared the PAM alkaline elution
crosslinking profiles of these cells and
untreated cells with normal levels of thiols. The
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cells which had undergone thiol-depleting treatment reached theirmaximum extent of
crosslinking in the one hour they were exposed to PAM while normal cells showed the
usual 12 hour delay. The maximum crosslinking reachedwas about the same as was the
later loss of crosslinks. Thus one factor in the slow onset of crosslinking by PAM in
Ross's and Hansson's cell studies compared to our isolated DNA studies may be the
influence of endogenous thiols. The mechanism of this influence is not known.
Interpretation ofDorr's results is complicated by the fact that L-buthionine (S/R)
sulfoximine pre-treatment seems go beyond removing any inhibition imposed on the
crosslinking reaction by endogenous thiols; PAM reaches its maximum extent of
crosslinking faster in cells after this pre-treatment than it does in our experiments with
isolatedDNA where there are no endogenous thiols. Little is known about how glutathione
can slow down crosslinking, not even whether glutathione reacts with PAM orHN2 and
somehow ties them up, orwhether glutathione is a part of a more complex cellular process.
It is also possible that L-buthionine (S/R) sulfoximine pre-treatment somehow activates
PAM for crosslinking. It would be possible to examine this question using our assay by
adding glutathione and/or L-buthionine (S/R) sulfoximine to the PAM andHN2 drug
solutions before running profiles of their reactions with DNA. If either of these chemicals
influence our results, they would have to do so by interacting with either the drug or the
DNA.
It should be noted that HN2 is also influenced by thiols. Murray andMeyn (1984)
used misonidazole to deplete the glutathione levels of cells within live C3Hmice, then
injected the mice with HN2. The mice were sacrificed and the cells ofvarious tissues and
of the FSa fibrosarcoma (which arises spontaneously in this strain) were tested for
crosslinking via the alkaline elution method and for glutathione by fluorimetry. Cells of
different organs reacted differently to this regimen, but there was a good correlation
between more severely depleted glutathione levels and more greatly enhanced crosslinking
in a given tissue. Unfortunately, since the cells were not growing in culture, the
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crosslinking reported is only a snapshot of its value at one time, not a profile over time, so
it cannot be compared with Dorr's PAM data. Still, glutathione may inhibit PAM andHN2
unequally.
Importance of Loss of Crosslinks
Both Ross andHansson attributed the differences in loss of crosslink to slower repair
ofPAM lesions than ofHN2 lesions. It should be noted that Ross's group did not specify
enzymatic repair, though that was implied, but Hansson's group did consider it likely that
enzymatic repairmechanisms were involved. That our results in a cell-free and enzyme-
free system are so similar to their in vivo results indicates that intrinsic chemical reactions
are amajor, if not the only, contributor to loss of crosslinks formed by PAM andHN-2.
This point is critical. Ross et al thought that a drug's effectiveness correlates with
the persistence of its crosslinks andHansson et al reported that cytotoxicity correlates with
the area under the crosslinking curve. Roberts, Brent, and Crathorn (1971) also put forth
the idea that restoration of the DNA and replication of theDNA are competing processes
with the outcome of the competition determining whether the cell will live or die. Murray
andMeyn (1986) showed that PAM cross links DNA ofChinese hamster ovary cells to
equal extents in various phases of the cell cycle, but that cells were nevertheless more
sensitive to PAM's cytotoxicity in Gl when there is little time to repair damagedDNA
before its replication in S. Any factor that slows the loss of crosslinks, increases the area
under the curve, or makes itmore likely that theDNA will still be crosslinked as DNA
replication begins should enhance the drug's effectiveness. Thus it is essential to further
explore the chemical mechanisms by which DNA interstrand crosslinks may be lost This
will be discussed further in Chapter 5.
Enzymatic Repair and Cell Susceptibility to PAM and HN2
This is not to deny the influence of enzymatic DNA repair systems on cell
susceptibility to drugs which crosslink DNA. Although
our data forHN2 in conjunction
with the in vivo studies suggest that differences in enzymatic repairmechanisms cannot be
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responsible for the faster loss ofHN2 crosslinking, thesemechanisms may be responsible
for some of the loss ofPAM crosslinks in vivo since PAM crosslinks were lost faster in
Hansson's cellular system than in our acellular one. Enzymatic repair could conceivably
happen in at least three contexts: removal of the drug when it has alkylated one base but has
not yet crosslinked to a second base, removal of one or both arms of the drug after
crosslinking, and repair ofDNA lesions left after the crosslink has been broken by either
purely chemical or enzymatic means.
There is no evidence for the removal ofPAM orHN2 fromDNA at the
monoalkylation step. Gibson, Zlotogorski, and Erickson (1985) used the alkaline elution
method to measure crosslinking by PAM, HN2, and two other drugs inMer+ andMer
human colon carcinoma cell lines. Mer (sometimes calledMex) stands formethyl excision
repair, and it had previously been shown thatMer cell lines are more susceptible to other
drugs which crosslinkDNA, especially the nitrosoureas. Further studies showed that
Mer"
cell lines lack a methyl transferase which was later renamed O ^-alkylguanine-DNA
alkyltransferase. This enzyme removes the chloroethyl group from the O position of
guanine, the initial alkylating site for the nitrosoureas. (Bodell et al, 1986; Ludlum, Mehta,
Tong, 1986; Brent, 1986; Brdar, 1986) Gibson's group found thatMer+ andMer cell
lines are equally susceptible to PAM andHN2, that their lesions are not susceptible to
repair by this enzyme system. This is reasonable given that the nitrogen mustards are
thought to alkylate at theN7 (not O ) position of guanine and that the entire drug
molecule minus a chloride (not a small chloroethyl group) forms the alkylating group. No
other enzyme systems have been suggested for removal of the initialmonoalkylating
groups of the nitrogen mustards.
There is some evidence for removal of one or both arms of the drug after
CTOSslinking. Kohn, Steigbigel, and Spears (1965), upon treating strains ofE. coli that
are unusually sensitive or resistant to the effects of ultraviolet light withHN2, found that
sensitivity toHN2 paralleled sensitivity to
ultraviolet light. Using analytical density
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gradient ultracentrifugation, they showed that crosslinking persisted in the sensitive strain
but was lost over time in the resistant and normal strains. They took this as evidence of a
common repair mechanism for UV andHN2 lesions ofDNA. It is difficult to reconcile
this data with our observation thatHN2 crosslinks disappearwith the same half life in vitro
that others report in vivo . One possible explanation is that theirmethodmay have
measured loss ofmolecularweight which could happen by DNA strand breaks as well as
by loss of crosslinks.
It should be noted that our data is compatible with mechanisms that repairDNA after
crosslinks have been lost by purely chemical means. The results obtained in cells by
Ross's group and Hansson's group would be expected to match our cell-free results if
repairmechanisms were operating after the chemical loss of crosslinks since both the
alkaline elution method and the ethidium bromide assay measure only one type of lesion,
the DNA interstrand crosslink. Sensitive cells might thus owe their increased sensitivity to
decreased ability to excise damagedDNA, synthesize new DNA fragments, or join the ends
ofDNA fragments in the processes ofDNA damage repair.
This seems to be the case in a number of experiments. Yin, Chun, and Rutman
(1973) found that HN2 alkylatesHN2 sensitive and resistant Lettre-Ehrlich cell lines
equally and that both cell lines lose crosslinks and excise damaged areas at the same rate.
However, the sensitive cells show much more nicking of the DNA while the resistant cells
show more rejoining of the DNA.
Dean, Johnson, and Tew (1986) found that ratmammary carcinoma cell lines
sensitive and resistant to HN2 have equal rates of crosslinking and loss of crosslinking, but
the sensitive strain has more sister chromatid exchanges (SCEs).
Fram, Sullivan, andMarinus (1986) evaluated the cytotoxicity ofHN2 and several
other anti-cancer drugs on a series ofE. coli strains deficient in various aspects of SOS
repair. SOS is a complex set of responses to damagedDNA in bacteria. Of the strains
they tested, only
recA"
and
uvrA"
strains experience more cytotoxicity than wild type cells
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when treated with HN2. The recA gene product acts as a protease on the lexA gene
productwhich normally represses the expression of a number of genes whose products are
associated with repair ofdamagedDNA. The uvrA gene product aids in repair bymaking
incisions at the site ofDNA damage (Zubay, 1983). Thus the sensitivity seems to be based
not on inability to lose the crosslink but on processes occurring after the crosslink is gone.
Our data is consistent with this type ofDNA repair.
Few experiments address reasons for different susceptibilities to PAM. Ducore et al
(1982) studied three Burkitt's lymphoma cell lines, one ofwhich was more sensitive to
PAM. All three cell lines had equal induction and loss of crosslinking as measured by the
alkaline elution method, but cells of the sensitive line were likely to lyse soon after
treatment with PAM.
It is clear from these experiments that enzymatic repair is important in cell resistance
to PAM and HN2, but is not necessarily the cause of the apparent loss of crosslinking over
time in alkaline elution experiments. Neither does it explain the differences in the rates of
apparent loss of crosslinking for PAM andHN2 in the alkaline elution experiments or in
our ethidium bromide assays. It is vital to continue to study purely chemical differences in
the formation and loss of crosslinks by PAM and HN2 in order to establish the basis for
their differences in clinical effectiveness. It is also important to establish whether the
apparent loss of crosslinking observed in alkaline elution and ethidium bromide assay
solutions is true loss of crosslinks or represents other processes such as loss ofmolecular
weight due to strand breaks. This will be discussed further in Chapter 5.
Summary of Profiles of PAM and HN2 with Calf Thymus DNA
PAM andHN2 at equal concentrations were shown to have similarmaximum extents
of crosslinking. However, these crosslinks were both gained and lost at different rates
with PAM crosslinking more slowly but forming more persistent crosslinks. HN2 was
shown to follow the same reaction profile whether the DNA was a part of a cell or purified
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in solution. PAM was shown to crosslink less and slower and to lose crosslinks quicker in
cells than in isolatedDNA. A number of possible explanations were explored including
transport processes, glutathione levels, and enzymatic repair of lesions.
That PAM andHN2 have different reaction profiles even with purifiedDNA points to
a need for further clarification ofpurely chemical differences in their reactions withDNA
and further study of the chemical mechanisms for loss of crosslinking. Chapters 3 and 4
will address differences in the reactions withDNA and Chapter 5 will examine the chemical
loss of crosslinks.
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Chapter 2: Drug Solution Stabilities
Introduction
One possible explanation for the differences in the time ofonset of the maximum
extent of crosslinking in PAM versusHN2 seen in the profiles discussed in Chapter 1 is
that the two drugs might have different stabilities in the 20mM, pH 7 sodium phosphate
buffer with 0.15M sodium chloride used to dissolve the drugs and DNA and to run the
reactions. Different solution stabilities for the two drugs could influence the profiles either
because one of the drugs might be destroyed significantly faster or because one of the
drugs might be converted more readily to the active intermediate in the drug solution. If
one drug is destroyed faster, it would be expected to give a lowermaximum extent of
crosslinking, but this was not seen in the profiles of Chapter 1 where equal drug
concentrations gave essentially equal maximum extents of crosslinking. If one drug is
activated more quickly, one would expect the profile to give an early maximum extent of
crosslinking for that drug, and this was observed in the reaction profiles.
Themethod used here to determine solution stability of the drugs is one thatmeasures
the crosslinking activity of the drug solutions as a function of time. Thus it is not
necessary to know the identity of the intermediate before determining its stability. We
measure the presence of the active intermediate not by a precise instrumentalmethod but by
its actions, its ability to crosslinkDNA.
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Procedures for Determining Drug Solution Stabilities
DNA-Drug Reactions
Drug solutions were prepared with concentrations of either 0.15 mM or 0.3 mM as
described above, but the predilution time was varied. A timer was started when the drug
pellet was dropped into buffer. Samples of the drug solutions were removed and added to
equal amounts ofDNA solution at certain times to initiate reactions. In each case, the
DNA/drug reaction was allowed to proceed for a set time, usually 5 to 20 minutes, at which
time a 20 uL aliquot of the reaction mixture was removed and placed in 1000 pL of
ethidium bromide assay solution. The alkaline assay solution destroys any unreacted drug
and provides a way to measure the relative concentration of duplex DNA. The fluorescence
of each sample was measured both before and after denaturation. Control samples were
prepared in the usual manner.
Calculation of Drug Solution Half Lives
Percent crosslinking for each sample was calculated in the usual manner. A line was
fit to percent crosslinking as a function of predilution time using the least squares method.
This line was extrapolated to obtain the percent crosslinking expected with a predilution
time of 0 minutes. Drug activity is defined as 1 .0 at the time the drug pellets are dropped
into buffer, but it is impossible to get data at tpredii.= 0 minutes because the drugs do not
dissolve instantly. The raw data was normalized to give drug activity at other predilution
times by the following equation:
Activity at tpredil=% crosslinking at tpredil. / extrapolated % crosslinking at tpredil=0min.
Activity was then plotted as a function ofpredilution time. One would expect this
plot to show exponential decay. That is true for the 47C plots, but in the 37C plots, the
trend looks more linear than exponential. For 47C plots, both an exponential fit for the
complete data and a linear fit for the linear region were tested. Correlation coefficients were
similar for both linear and exponential fits, and half-lives obtained from the two types of
fits fell within 7 minutes of each other. Since the half lives obtained at the two
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temperatures were to be compared, half lives were calculated by a least squares linear fit for
the 37C plots and by a least squares linear fit to the linear regions of the 47C plots. The
half-life of the drug solution (by definition, the time at which the solution has half of its
maximal activity) was calculated from the slope of this line (note that the intercept is
necessarily 1.0) using the following equation.
t1y2=-l/(2xslope)
This equation is applicable only withmaximum activity (intercept) normalized to 1 and for
data with a linear trend.
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Results
PAM
Figures 2-1, 2-2 and 2-3 summarize the results ofPAM stability experiments at 37C
and 47C. 27C stability was also of interest, but the reaction did not proceed to an
appreciable extent at this temperature. Note that in the 47C experiment only the first six
points (predilution times to 120 minutes) were used in the least squares line fitting since
later points were obviously non-linear.
From the figures, it appears that the half-life for PAM at 37C is about 136 minutes
plus orminus 10 minutes. At 47C the half-life for PAM is about 70 minutes, around
half its value at the lower temperature. Presumably, the half-life of PAM at 25C is
somewhat longer than 136 minutes.
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Figure 2-1 PAM hydrolysis at 37C, Trial 1, [Drug]/[P]=5, RG1-133.
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Figure 2-2 PAM hydrolysis, 37C , Trial 2, [Drug]/[P]=0.1, RG2-145.
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Figure 2-3 PAM hydrolysis at 47C, [Drug]/[P]=1, t-half=70 min. (6 points), MK1-40.
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HN2
Figures 2-4, 2-5, and 2-6 summarize the results ofHN2 stability experiments at
37C and 47C. As with PAM, 25C stability was desired but not obtained due to the
slowness of the reaction. For the 47C experiment, only the first five points were used to
determine the line.
Although the figures show longer half-lives for longer reaction times, half lives for
HN2 based on reaction times less than or equal to 20 minutes are similar to those for PAM:
about 142 minutes plus or minus 10 minutes at 37C and about 70 minutes at 47C.
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Figure 2-4 HN2 hydrolysis at 37C, Trial 1, [Drug]/[P]=1 with [P]=0.16 mM, RG1-57
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Figure 2-5 HN2 hydrolysis at 37C, Trial 2, [Drug]/[P]=1 with [P]=.16 mM, RG1-67
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Figure 2-6 HN2 hydrolysis at 47 C, [Drug]/[P]=1 with [P]=.15mM. For 10 min.
rxn.half-life= 70 min. based on first 5 points. MK1-24.
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Discussion
Comparison of PAM and HN2 Solution Stability
Several conclusions arise from the solution stability data. First, PAM and HN2 have
remarkably similar half-lives in 20mM pH 7 sodium phosphate buffer at both 37C and
47C. Therefore, it is unlikely that differential stability accounts for the differences
between the drugs in either clinical use or in vivo and in vitro experiments. Second, the
activity for either drug can be calculated from the least squares line for loss of activity at a
particular temperature based on the theoretical concentration and the predilution time. At
37C, about 93% ofPAM activity is present after the usual 20minute predilution time and
about 97% ofHN-2 activity is present after the usual 10minute predilution time. At 47C,
86% ofPAM activity and 93% ofHN2 activity are present after these same predilution
times.
PAM and HN-2 Decomposition in the Literature
The mode of decomposition ofPAM has been examined in some detail. Chirigos and
Mead (1964) sought to use fluorimetry to measure the concentration ofPAM, but found a
number of confounding factors which are of interest in the present work. Although
fluorescence was proportional to concentration in freshly made solutions ofPAM, the
reading increased over time and reached amaximum within 3 hours at 37C in 10"^ M
NaCI. Thus the hydrolysis product was even more fluorescent than PAM itself. This
observation combined with an earlier observation that aqueous solutions ofPAM liberate
HC1 led to the following equation for hydrolysis ofPAM:
R(CH2CH2C1)2 + 2H20 > R(CH2CH2OH)2 + 2HC1
Intermediate species were not reported though it is thought that PAM decomposes in two
steps, tomonohydroxymelphalan and then to dihydroxymelphalan. Over the same time
period, they saw no change in the UV spectrum, indicating that the benzene ring ofPAM
remained intact They also noted that PAM is less stable in phosphate buffer solutions than
in saline, being lost by alkylating phosphate ions as well as by hydrolysis.
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Chang et al (1979) tested two alternate explanations, initially suggested by Ross, for
PAM's greater stability in saline solutions. The presence of chloride ion in solution might
suppress PAM's dissociation , or chloride ions might compete with OH- to associate with
the carbocation initially formed, restoring the PAM molecule as shown in Figure 2-7. The
second hypothesis was supported by the fact that PAM disappeared at the same rate in
0.156M KBr as in water and thatHPLC showed that the products included
monohydroxybromomelphalan, monobromomelphalan, and dibromomelphalan along with
melphalan, monohydroxymelphalan, and dihydroxymelphalan; the carbocation can react
with halides ions in solution so PAM can be restored from the carbocation. It is not known
whetherHN2 reacts in a similar manner.
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Kallama andHemminki (1986), also using HPLC, reported anothermode of
decomposition for adducts ofphosphoramidemustard, cleavage of the phosphoramide
bond yielding nornitrogen mustard. It is also possible that PAM undergoes a similar
reaction in pH 7 20mM phosphate buffer solution over a long period of time. Evidence of
this is that PAM solutions stored frozen at -70C and examined 6 months later had lost
theirUV peak. (Christian G.Reinhardt, unpubtished data)
Bosanquet (1985) followed the course ofPAM decomposition by monitoring
melphalan itselfplus the intermediatemonohydroxymelphalan and the ultimate product
dihydroxymelphalan using HPLC. He found that PAM was about 30% less stable in
phosphate-buffered saline than in normal (150mM) saline at 5, 21.5, and 24.5C. This is
consistent with the ideas mentioned above. The half-life in saline at 37C was 2.7 hours .
If this 30% relationship holds true at higher temperatures, PAM would be expected to have
a half-life of 1 13 min. at 37C in phosphate buffer. The half-life for PAM activity reported
here is in fairly close agreement (136 min. at 37C).
As discussed in Chapter 1, both Ross et al (1978) andHansson et al (1987) thought
that PAM's crosslinking reaction with DNA must be a 2-step reaction in which the first step
would quickly tie up PAM and prevent its decomposition and the second step would slowly
produce the crosslink. Their profiles show that crosslinking continues to increase with the
maximum extent of crosslinking at 12 hours, long after all of the drug should have decayed
based on the PAM solution half-lives then available. Ross supported this with a half-life
for PAM of only an hour at pH 7 and 37C in 0. IM pH 7.4 phosphate buffer based on
work ofWilliamson andWitten (1967). Hansson used the same reasoning and the same
half-life based on the aqueous stability reported by Chang et al (1979). The PAM half-life
reported here is about twice as long (136 min. at 37C) and therefore not compelling as
evidence for the 2-step reaction. Applying the rule of thumb thatmost (97%) of the activity
decays within 5 half-lives, the activity ofPAM in solution would be quite low by about
1 1.5 hours, very close to the 12 hour time at which these two groups saw the peak in
47
extent of crosslinking. With our stability data for PAM, which agrees with Bosanquet's, it
is not necessary to invoke a slow second step to explain Ross's orHansson's data. A slow
second step is not ruled out as long as it does not take too long. One caution in interpreting
any half-life data is the known influence ofother chemicals in themedium on the stability
of a PAM solution: none of the half-lives cited here are directly applicable to Ross's or
Hansson's experiments because none used the same medium.
HN2 solution stability does not appear to be discussed in the literature, so the results
presented here may serve as a basis for future work.
Significance of New Technique to Measure Drug Activity
The technique ofmeasuring PAM andHN-2 decomposition in terms of loss of
activity is significantly different than techniques reported in the literature. Previous
methods used high precision instrumentation such as HPLC andUV and fluorescence
spectroscopy tomeasure the disappearance of the drug itself or the appearance of the
decomposition products. Our technique, while less precise, measures the disappearance of
whatever the active intermediate is without having to identify the relevant species. Because
the active species is neither identified nor isolated, the decay is not a simple unimolecular
reaction. The rate of disappearance of the active intermediate is influenced by its rate of
formation from drug, its possible reactions with chloride and phosphate ions, its rate of
hydrolysis, and its rate of reaction with DNA as shown in Figure 2-8. This may explain
why the 37C decay curves do not appear as first order exponentials
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Figure 2-8 Schematic ofDisappearance ofActive Drug Intermediate
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Summary of PAM and HN2 Solution Stability
A new techniquewas used to measure the crosslinking activity ofPAM andHN-2
solutions as a function of time.The half-life values ofPAM andHN2 activity in pH7 20
mM phosphate buffer with 0.15 MNaCI are shown to be nearly identical at 37 and 47C
so differences in the reaction profiles of the two drugs with DNA cannot be due to
differential drug stability. The half-life ofPAM activity we report is longer than the half-
lives ofPAM previously reported in the literature and is more consistent with the prolonged
rise in crosslinking ofDNA by PAM solutions.
50
Chapter 3: Influence of Drug Concentration on Reaction Rate
Introduction
Crosslinking reactions are carried out with a constantDNA concentration and varying
drug concentrations to determine the order of the reaction with respect to the drugs.
Combinedwith previous experiments which established the orders of the reactions with
respect to DNA, this information allows evaluation of proposedmechanisms forDNA/drug
interaction. Proving the DNA crosslinking reactions of both PAM and HN2 to be pseudo
first order will allow for the use of an Arrhenius plot to determine the activation energy and
steric factor for each reaction.
Itwas also desirable to compare the ratio of the pseudo first order rate constants for
PAM andHN2 with the ratio of the time needed for each drug to produce its maximum
extent of crosslinking in the profiles ofChapter 1. If the ratios are similar, it follows that
the time lag for PAM is explainable entirely on the basis of a smaller pseudo first order rate
constant.
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Procedures
Reaction Procedures
All reaction procedures were as described under general procedures. DNA and drug
solutions were equilibrated to 37C and reactions were run at that temperature using a heat
block to maintain the constant temperature. Equal volumes ofDNA and drug solutions
weremixed to initiate reactions, and 20 pi. aliquots of the reaction mixture were removed
into 1000 pi portions of ethidium bromide assay at set times. Fioo and Fd were measured
for the samples and for appropriate controls as described previously. Percent crosslinking
was calculated for each sample.
Analysis of Data
Crosslinking was plotted as a function of time for each drug concentration used. The
initial rate of a reaction was calculated as the slope of the initial linear portion of the
concentration versus time plot. Although the plots would be expected to go through the
origin, this was not forced in the least squares linear fits. Nearly all of the plots had small
positive y-intercepts, although a few had negative y-intercepts. Perhaps the intrinsic Fd
control values are somewhat different than the Fq values for control samples containing
DNA in the absence of drugs, due to experimental error. The standard deviation of the
slope was calculated for selected plots and was used to calculate 95% confidence intervals.
For each drug, the initial slopes were plotted as a function of drug concentration and
the plots were examined for a linear trend.
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Results
PAM
Figures 3-1 to 3-5 show initial reaction profiles of PAM using a variety of drug
concentrations (expressed as [Drug]/[phosphate]) with a constantDNA concentration. All
reactions were at 37C. The data from Figures 3-1 and 3-2 were combined to calculate the
initial slope (0.33 % /min. plus orminus 0.07 % /min.) to use for PAM for 37C and
[Drug]/[phosphate] =0.1 for the Arrhenius plot in Chapter 4. Figure 3-6 summarizes the
effect of drug concentration on initial reaction rate. It can be seen that the dependence of
initial reaction rate on drug concentration for PAM is approximately linear.
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PAM [Drug]/[Phosphate]=0.1 Initial Reaction
% Crosslinking
15 20 25
Time (minutes)
30 35 40
Figure 3-1 Initial Rate ofDNA Crosslinking by PAM at 37C. [Drug]/[P]=0.1 with
[P]=0.16 millimolar, Trial 1. Initial Slope (first 28 minutes) is 0.40% perminute plus or
minus 0.06 % per minute. MK1-78.
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PAM [Drug]/[Phosphate]=0.1 Initial Reaction
% Crosslinking
2 4 6 8 10 12
Time (minutes)
18 20
Figure 3-2 Initial Rate ofDNA Crosslinking by PAM at 37 Degrees Celsius.
[Drug]/[P]=0.1 with [P]=0.16 millimolar, Trial 2. Initial Slope (20 minutes) is 0.19% per
minute plus orminus 0.06 % perminute. MK1-62.
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PAM [Drug]/[Phosphate]=0.19 Initial Reaction
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Figure 3-3 Initial Rate ofDNA Crosslinking by PAM at 37C. [Drug]/[P]=0.19 with
[P]=0.16 millimolar. Initial Slope (first 14 minutes) is 1.20% perminute. Regression
Coefficient is 0.990. MK1-58.
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PAM [Drug]/[Phosphate]=0.35 Initial Reaction
% Crosslinking
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Figure 3-4 Initial Rate ofDNA Crosslinking by PAM at 37C. [Drug]/[P]=0.35 with
[P]=0.16 millimolar. Initial Slope (first 14 minutes) is 2.60% perminute, r squared is
0.977. MK1-54.
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Figure 3-5 Initial Rate ofDNA Crosslinking by PAM at 37C. [Drug]/[P]=0.5 with
[P]=0.16 millimolar. Initial Slope (first 5 minutes) is 3.37% perminute. Regression
Coefficient is 0.992. MK1-70.
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PAM Crosslinking Initial Slope as a Function of [Drug]/[Phosphate]
Initial Slope
% perminute
0.05 0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45 0.5
[D]/[P] Ratio
[P]=0. 16 millimolar
Figure 3-6 Summary ofDependence of Initial Cross-Link Rate on PAM Concentration at
37C. Slope is 7.75. Regression Coefficient is 0.982. DNA MW=9.7 x 107. Buffer
was 20 mM pH 7 sodium phosphate with 0.15 M NaCI.
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HN2
Figures 3-7 to 3- 1 1 show initial reaction profiles ofHN2 using a variety of drug
concentrations (expressed as [Drug]/[phosphate]) with a constantDNA concentration. All
reactions were at 37C. Figure 3-12 summarizes the effect of drug concentration on initial
reaction rate. HN2 is also shown to have a linear dependence of initial reaction rate on
drug concentration.
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HN2 [Drug]/[Phosphate]=0.1 Initial Reaction
% Crosslinking
6 8 10 12 14 16 18 20
Time (minutes)
Figure 3-7 Initial Rate ofDNA Crosslinking by HN-2 at 37C. [Drug]/[P]=0.1 with
[P]=0. 16 millimolar. Initial Slope (first 16minutes) is 2. 1% perminute plus orminus
0.1% per minute. MK1-42.
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HN2 [Drug]/[Phosphate]=0.2 Initial Reaction
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Figure 3-8 Initial Rate ofDNA Crosslinking by HN-2 at 37C. [Drug]/[P]=0.2 with
[P]=0. 16 millimolar. Initial Slope (first 8 minutes) is 3.56% perminute. Regression
Coefficient is 0.981. MK1-46.
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HN2 [Drug]/[Phosphate]=0.3 Initial Reaction
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Figure 3-9 Initial Rate ofDNA Crosslinking by HN-2 at 37C. [Drug]/[P]=0.3 with
[P]=0.16 millimolar. Initial Slope (5 minutes) is 4.44% perminute. Regression
Coefficient is 0.993. MK1-144.
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HN2 [Drug]/[Phosphate]=0.37 Initial Reaction
Figure 3-10 Initial Rate ofDNA Crosslinking by HN-2 at 37C. [Drug]/[P]=0.37 with
[P]=0.16 millimolar, Trial 1. Initial Slope (first 5 minutes) is 6.33% perminute.
Regression Coefficient is 0.981. MK1-34.
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HN2 [Drug]/[Phosphate]=0.37 Initial Reaction
% Crosslinking
Figure 3-11 Initial Rate ofDNA Crosslinking by HN-2 at 37C. [Drug]/[P]=0.37 with
[P]=0. 16 millimolar, Trial 2. Initial Slope (first 3 minutes) is 9.66% perminute.
Regression Coefficient is 0.990. MK1-128.
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HN2 Crosslinking Initial Slope as a Function of [Drug]/[Phosphate]
Summary ofDependence of Initial Cross-Link Rate
on HN-2 Concentration at 37 degrees Celsius
Slope is 21.52.
Regression Coefficient is 0.745.
Initial Slope
% perminute
0.15 0.2 0.25
[D]/[P] Ratio
[P]=0. 16 millimolar
0.35 0.4
Figure 3-12 Summary ofDependence of Initial Cross-Link Rate on HN-2 Concentration
at37C. Slope is 21.52. Regression Coefficient is 0.745. DNA MW=9.7 x 107. Buffer
was 20 mM pH 7 sodium phosphate with 0.15 M NaCI.
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Discussion
Comparison of PAM and HN2
Tables 3-1 and 3-2 summarize the initial rates at various [drug]/[phosphate] ratios and
the slopes of the initial reaction rate versus drug concentration plots for PAM andHN2. It
is apparent that PAM has slower initial rates at all drug concentrations and a less
pronounced increase upon adding more drug than HN2 has. This agrees with the profiles
ofChapter 1 in which PAM tookmuch longer to reach maximum crosshnking. The ratio of
the pseudo first order rate canstant for HN2 to that ofPAM is about 2.8 . The ratio of the
time necessary to reach maximum extent of crosslinking for PAM to that forHN2 in vitro
is in the range of 2 - 6. Thus the differences in initial reaction rates satisfactorily explain
the differences in time needed to reach maximum extent of crosslinking for PAM andHN2
which were observed in the reaction profiles reported in Chapter 1.
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Table 3-1
[D]/[p]=0.1 [D]/[p]=0.2 rD]/[p]=0.3 rD]/[p]=Q.37 [D]/[p]=0.5
HN2 Rate 2. 1 plus or
minus 0. 1
%/min.
3.6%/min. 4.4%/min. 6.3%/min.
9.7%/min.
not available
PAM Rate 0.33 plus or
minus
0.07%/min.
(combined
data)
1.2%/min. not available 2.6%/min. 3.4%/min.
Ratio
HN2/PAM
about 6 about 3 not available about 3 not available
Table 3-1 Summary of Initial Reaction Rates of PAM andHN2 with Ultra-Pure Calf
Thymus DNA (molecular weight = 9.7 X 107) at 37C in pH 7, 20 mM sodium phosphate,
0.15 M NaCI buffer.
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Table 3-2
Slope of Initial
Reaction Rate
vs.Drug Conc.plot
Time required to
acheivemaximum
extent of
crosslinking
HN2 20 50-90 min.
PAM 8 180-300 min.
Ratio: HN2/PAM about 3
Ratio: PAM/HN2 range 2-6
Table 3-2 Pseudo First Order Rate Constants: Initial Reaction Rates as a Function of
Drug Concentration for PAM andHN2 with Ultra-Pure Calf Thymus DNA (molecular
weight = 9.7 X 107) at 37C in pH 7, 20 mM sodium phosphate, 0. 15 M NaCI buffer.
Error is about plus or minus 20% based on values reported in Table 3-1.
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Linearity of Initial Rate Versus Drug Concentration Plot
The strong linear trend for PAM and the moderate linear trend forHN2 for the plot of
initial rate versus drug concentration implies that the reactions are first order with respect to
PAM orHN2 concentration. It had been shown previously that the PAM reaction is zero
orderwith respect to DNA concentration and that the HN2 reaction is first order with
respect toDNA concentration (Richard A. Grucza, unpublished data). These facts taken
together support a bimolecular reaction betweenDNA and the HN2 active intermediate but
a unimolecular reaction between DNA and the PAM active intermediate. The implication is
that, while theHN2 active intermediate is formed quickly and/or is stable and builds ups in
solution, the PAM active intermediate is formed slowly and/or is unstable such that it does
not build up in solution. Thus the rate-limiting step of the HN2 reaction would involve
HN2 active intermediate molecules colliding with and alkylatingDNA molecules, a second
order step. But for PAM, the rate-limiting step would be the formation of the active
intermediate, a unimolecular step followed by quicker alkylation ofDNA by the PAM
active intermediate. This might help to explain the slow initial rate and delay in maximal
crosslinking for PAM.
The fact that the concentration dependence curve are linear also allows the use of the
Arrhenius plot to analyze the temperature dependence of the reactions ofPAM andHN2
with DNA. This analysis will be discussed in Chapter 4.
Proposed Reaction Mechanisms in the Literature
There is agreement thatHN2 alkylatesDNA via a cyclic azMdinium ion as shown in
Figure 3-13. (Williamson andWitten, 1967, Connors, 1975) It was also suggested by
Kohn, Spears, andDoty (1966) that the formation ofdenaturation-resistantDNA (in
then-
case, denaturation was achieved through the use of formamide or sodium hydroxide)
shows a first order dependence on HN2 concentration. Since reaction of the aziridinium
ion with DNA is the slow step, the kinetics of the reaction should depend on both DNA and
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HN2 concentrations. Our results do show a first order dependence of the reaction rate with
respect to both HN2 concentration andDNA concentration and thus support this
mechanism. This is an Sn2 type of reaction.
On the other hand, there is much disagreement about PAM's reaction mechanism.
Some authors, reviewed by Connors (1975), think that PAM follows the same mechanism
asHN2 but with the first step being slower and the alkylation step being faster. The slow
step would be the unimolecular cyclization and the reaction is Snl type. Others think that
PAM reacts via a carbocation as shown in Figure 3-14. This is also Snl type . It should
be noted that this primary carbocation would be highly unstable. Since both proposed
mechanisms are Snl type, the reaction rate is independent ofDNA concentration.and our
results do not distinguish between them.
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CH,N
CHjCHjCl
CH2CH2Q
cn
CH,N
HN2 Mechanism
=^ CH,N I +
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CH2CH2CI
CH2CH2Y
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CHjCHCl
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? CH3N
\
CHjCHa
ci- Faster
Slower
Y represents a nuclophilic reagent such as DNA
Figure 3-13 HN2 Reaction Mechanism for Crosslinking DNA Via an Aziridinium Ion
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One Proposed PAM Mechanism- Carbocation
CH.CH.Q
PheN " PheN + ci- Slower
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Figure 3-14 A Possible Mechanism for PAM Crosslinking ofDNA Via a Carbocation
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Summary of Concentration Dependence
Both PAM andHN2 show an approximately linear relationship between drug
concentration and initial rate of crosslinking, implying that the DNA interstrand
crosslinking reactions ofPAM andHN2 are pseudo-first order with respect to drug
concentration. The differences in initial rreaction rates have also been shown to be
adequate to explain the slow onset ofPAM-inducedDNA interstrand crosslinks compared
to the faster onset ofHN2-inducedDNA interstrand crosslinks.
Our data are consistentwith the previous suggestion thatHN2 reacts withDNA via a
cyclic aziridinium ion in an SN2-type reaction while PAM reacts with DNA via either a
cyclic aziridinium ion or a carbocation in an SNl-type reaction.
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Chapter 4: Influence of Temperature on Reaction Rate
Introduction
It is possible that the differences between the time-dependent reaction profiles of
PAM and HN2 reported in Chapter 1 are due to differences in activation energy and/or
steric factors of the interactions of the two drugs withDNA. In this chapter, initial reaction
rates at various temperatures are used to construct Arrhenius plots. If these plots show
linear trends, then relative activation energies and steric factors can be extracted from the
plots.
A generalized Arrhenius plot of In k versus 1/T is shown as Figure 4- 1 . If the plot is
linear, it implies that the drug is reacting with a unique site in DNA or with several sites
having very similar activation energies. If the activation energies (calculated from the fact
that the slope of the plot equals -Eact/R) for the two drugs are similar, it implies that their
sites of action are similar. If the preexponential factors A (the intercept of the plot is InA)
for the two drugs are similar, then those drugs have similar steric factors in their
interactions with DNA.
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Generalized Arrhenius Plot
In A
slope=-E / R
act
1/T, K
Figure 4-1 Generalized Arrhenius plot k=initial slope of a time-dependent reaction
profile at a particular temperature.
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Procedures
Initial reaction profiles were obtained by themethod described in Chapter 3 with the
following differences: The [Drug]/[Phosphate] ratio was 0.1 for all experiments. The 0C
experiments were performed using a heat block in an ice bath, the 24.5C experiments
used a heat block in a water bath, and the 37C and 47C experiments used the heat block
with an electrical thermostat All temperatures were measured by means of a thermometer
in the heat block near the reaction vessel.
Reaction mixtures were sampled, Fioo and Fd were measured, and percent
crosslinking was calculated for each sample as described in Chapter 3. For each reaction,
percent crosslinking was plotted as a function of time. Linear regression was used to fit a
straight line to the initial linear portion of the curve; the slope of this line is the initial
reaction rate. For each drug, an Arrhenius plot was made of the natural log of the slope
versus the inverse of the temperature (K). A line was also fit to this data by linear
regression, and its slope and interceptwere determined.
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Results
PAM
Figures 3-1, 3-2, 4-2, and 4-3 show initial reaction profiles for PAM using a variety
of temperatures with a drug concentration (expressed as [DrugMphosphate]) of 0.1.
Results for 0C are not shown since essentially no crosslinking took place dining the first
90minutes. Figure 4-6 summarizes the effect of temperature on initial reaction rate.
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Figure 4-2 Initial Rate ofDNA Crosslinking by PAM at 24.5C. [Drug]/[P]=0.1 with
[P]=0.16 millimolar. Initial Slope (40 minutes) is 0.16% perminute plus orminus 0.02%
perminute. MK1-82.
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Figure 4-3 Initial Rate ofDNA Crosslinking by PAM at 46C. [Drug]/[P]=0.1 with
[P]=0.16 miltimolar. Initial Slope (20 minutes) is 1.15% perminute plus or minus 0.04%
per minute. MK1-102.
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HN2
Figures 3-7, 4-4, and 4-5 show initial reaction profiles forHN2 using a variety of
temperatures with a drug concentration (expressed as [DrugMphosphate]) of 0.1. Results
for 0C are not shown since essentially no crosslinking took place during the first 63
minutes. Figure 4-6 summarizes the effect ofdrug concentration on initial reaction rate.
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HN2 Initial Reaction at 26C
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Time (minutes)
Figure 4-4 Initial Rate ofDNA Crosslinking by HN-2 at 26C
[Drug]/[P]=0.1 with [P]=0.16 mM. Initial Slope (first 10 minutes) is 0.42% perminute
plus or minus 0.2% per minute. MK1-98.
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HN2 Initial Reaction at 47C
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Figure 4-5 Initial Rate ofDNA Crosslinking by HN-2 at 47C. [Drug]/[P]=0.1 with
[P]=0.16 mM. Initial Slope (first 5.5 minutes) is 3.4% per minute plus orminus 0.4 %
per minute. MK1-94.
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in % per min.)
PAM and HN2 Arrhenius Plots
PAM
HN2
1/T (K) X 1000
Figure 4-6 Effect of Temperature on Initial Crosslinking Rates ofPAM and
HN2.[Drug]/[P]=0.1 with [P]=0.16 mM. For PAM, slope = -8.4 and intercept = 26. For HN2,
slope=-9.7 and intercept=32. DNA MW=9.7 x 107. Buffer was 20 mM pH 7 sodium phosphate
with 0.15 M NaCI.
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Discussion
Comparison of PAM and HN-2 Temperature Dependence
The Arrhenius plots for both PAM and HN2 appear to be linear for the few
temperatures available at this time. This implies that each drug is reactingwith a unique site
in DNA, or that all major reaction sites in DNA require a similar activation energy. Since
this is an important point, future experiments should include initial reaction rates formore
temperatures for the two drugs in order to better evaluate the linearity of the Arrhenius
plots.
The slope of an Arrhenius plot is equal to -Ea/R, but since the initial reaction rates are
expressed as % crosslinking perminute rather than moles ofproduct perminute, the slopes
of these plots cannot be used to derive numerical values for the activation energies of the
PAM andHN2 reactions. However, the ratio of the slopes of the PAM andHN2
Arrhenius plots gives the ratio of the activation energies for the reactions ofHM2 and PAM
with DNA. Figure 5-6 emphasizes the similarities of the slopes of PAM's and HN2's
Arrhenius plots. Within experimental error, the slopes are indistinguishable, implying that
the two drugs require a similar activation energy to crosslinkDNA. This is surprising in
light of the faster reaction rate ofHN2.
The y-intercept of an Arrhenius plot equals InA whereA is the pre-exponential or
steric factor for the equation k=Ae~Ea/RT. As with the activation energy, we cannot derive
a numerical value for the steric factor because our initial rates are expressed as % per
minute instead ofmoles per minute. Since our goal is simply to compare the steric factors
for PAM and HN2, we can take a ratio of the steric factors which is the ratio of e raised to
the value of the intercept forHN2 to e raised to the value of the intercept for PAM. This
equals e raised to the difference between the HN2 and the PAM intercepts. This equals
e(32-26) or a steric factor 400 times more favorable forHN2. This more than compensates
forHN2's larger activation energy and explains why HN2's reaction rate is so much faster
than PAM's.
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Mechanisms in the Literature Revisited
Hemminki andLudlum (1984), reviewing the field, indicated thatDNA crosslinking
agents which are known to react via an Snl type mechanism, such as the nitrosoureas, tend
to react with oxygen atoms of nitrogenous bases and of the phosphate backbone.
However, the Arrhenius data here suggest thatHN2 and PAM react at the same site which
is known to be the N-7 position of guanine formonoalkylation and assumed to be the same
for the crosslinking step. If the tendency is really that agents which react via carbocations,
which the nitrosoureas do, tend to react with oxygen atoms of the nitrogen bases, then our
Arrhenius data would imply that PAM does not react via a carbocation to attack oxygen
atoms but reacts via a cyclic aziridinium ion just like HN2. If this is true, then the contrast
between the first order dependence of the HN2 reaction on DNA concentration and the zero
order dependence of the PAM reaction on DNA concentration would not be due to the
formation of different intermediates (aziridinium ion forHN2 and carbocation for PAM).
Instead, this difference would be due to differences in the rate of formation of the same
type of intermediate, the aziridinium ion, in competition with the reaction of that ion with
the DNA.
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Summary
By plotting the natural log of the initial reation rate against the reciprocal of the
absolute temperature for the reaction, Arrhenius plots were generated for PAM and HN2.
Both plots appear to be linear, so it is assumed that each drug reacts at one DNA site or a
few sites which have similar activation energies. From these plots, the relative activation
energies and steric factors for the two drugs were calculated. Surprisingly, HN2 and PAM
have similar activation energies. As expected, PAM has a lower, reaction-slowing, steric
factor.
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Chapter 5: Loss of Crosslinking
Introduction
The difference in the rates of loss ofPAM-induced and HN2-induced DNA
interstrand crosslinks shown in the profiles ofChapter 1 is striking. It is possible that
understanding the mechanisms of differential loss of crosslinks will allow rational design
ofmore effective, less toxic anticancer drugs. However, itmust be recalled that the half
lives reported in Chapter 1 are only apparent half lives. In the profiles, there was no
removal of unreacted drug and more crosslinks presumably formed even as earlier ones
were lost, extending the apparent half-life beyond the true half-life. In addition, some loss
of fluorescence may be due to breakage of the DNA and not to loss of the crosslinks
themselves. The experiments ofChapter 5 were designed to provide more information
about the fates of PAM and HN2 DNA interstrand crosslinks. The studies of the
dependence of reaction rate on temperature provide true half lives for the crosslinks after
removal of the unreacted drugs. The study of the effects of our alkaline ethidium bromide
assay procedure on closed circularDNA sheds light on the role ofDNA strand breaks in
the apparent loss of crosslinks in our procedure.
We had also hoped that the technique of separating unreacted drugs from the DNA
would also allow us to see the crosslinking (second) step apart frommonoalkylation. That
is, monoalkylated DNA coming through the column is expected to gain crosslinking over
time as the second reactive arm of the drug forms the crosslink.
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Procedures
Exclusion Chromatography Separation of Unreacted Drugs
It is necessary to separate unreacted drug frommonoalkylatedDNA in order to
investigate the true kinetics of the loss of crosslinks. We use a separation method based on
a technique developed by McGhee and von Hippel (1977) to remove small molecules from
solutions of polynucleotides without diluting the solution. A small tube is packed with P-4
gel hydrated with buffer solution. Excess buffer is removed from between the beads by
centrifuging the tube. A sample containing buffer, DNA, and drug is added to the column
and the tube is again centrifuged. Small molecules such as unreacted drug move into the
beads and are retained on the column while largermolecules such as monoalkylated and
crosslinkedDNA leave the column and are collected for crosslinkmeasurements.
Two types of control experiments were done to verify the success of the separation.
In order to confirm that unreacted drug is retained quantitatively, samples containing only
buffer and drug were passed through the column and the liquid coming off the column was
tested for its ability to crosslink DNA. This liquid did not crosslink DNA. In order to
determine whetherDNA comes through undiluted and undamaged, samples containing
only buffer and duplex DNA were passed through the column. The DNA was then added
to a portion of ethidium bromide assay solution which gave the same fluorescence as
another a similarmixture in which the DNA was added to the assay without first going
through the column. (R. Gruszca, unpublished data)
Preparation ofDNA and drug solutions and initiation of reactions followed standard
procedures until the time of separation of unreacted drug from the reaction mixture. A
Biorad P-4 gel exclusion column was used to remove unreacted drugs from reaction
mixtures. The reaction mixtures, minus unreacted drugs, were then sampled at appropriate
intervals. Samples were placed into tubes of ethium bromide assay solution , Fioo and
Fden readings were taken, and percent crosslinking was calculated as usual.
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Percent crosslinking was plotted as a function of time and the curves were fit to the
linear decay equation shown below using a least squares fit.
% crosslinking = Ae~kt + b
In this context, A is the amount of initial crosslinking in excess of the residual, k is the rate
constant for exponential decay, t is time, and b is residual crosslinking (that which seems to
resist being lost).
Closed Circular DNA Ethidium Bromide Assay for Strand Breaks
Lown (1979) described a method of using PM2 closed circular DNA to determine
whether a chemical agent is capable of introducing breaks in the sugar-phosphate backbone
ofDNA. The method is summarized in Figure 5-1. Because of its supercoiling, native
PM2 would not be expected to separate into two strands during our denaturation protocol,
regardless of the presence or absence of PAM- orHN2-induced DNA interstrand
crosslinks. Thus, in the absence of drug, a sample ofPM2 in ethidium bromide assay is
expected to have the same Fioo and Fd- In addition, the supercoiling of PM2 closed
circularDNA diminishes the number of sites available for intercalation of ethidium bromide
resulting in a lower Fioo than would be expected for linearDNA of the same molecular
weight. However, if the drugs introduce breaks in the DNA's sugar-phosphate backbone,
the supercoiling is relaxed and the Fioo will increase. Thus an increase in the Fioo of a
PM2 solution exposed to PAM orHN2 would indicate that, in addition to crosslinking
DNA, the drugs also introduce strand breaks. If there is no such increase in Fioo, then the
drugs are not degrading the DNA in this way.
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PM2 Nicking Assay
Native PM2
Closed Circular DNA
Supercoiled
Fluorescence = Fjqq
PM2
after denaturation
protocol
Fluorescence = F<
PM2
if nicking occurs
Fluorescence > F100
100
Figure 5-1 PM2 Nicking Assay. Supercoiled PM2 closed circularDNA is expected to
have the same fluorescence before and after the ethidium bromide alkaline denaturation
protocol because supercoiling prevents separation of the strands. But if the DNA backbone
is nicked, supercoiling relaxes and the Fioo should increase due to more intercalation of
ethidium bromide. Fden should decrease because the strands are free to separate (assuming
no covalent crosslinks).
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Results
PAM
Figure 5-2 shows the crosslinking profile for a PAM-DNA reaction mixture in which
unreacted drug was removed at 20 minutes into the reaction. The main features of the
reaction are the half-life of about 180 minutes (3 hours) (95% confidence interval gave 2 to
5 hours for the half-life) and the large fraction of crosslinks that seem to resist decay or
which are decaying on a much longer time scale. Another feature of interest is the lack of
additional crosslink formation after unreacted drug has been removed. Note that each time
has triplicate crosslinking data.
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Loss of PAM Crosslinks After Removal of Unreacted Drug
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Figure 5-2 Loss of Crosslinking from ReactionMixture after Removal ofUnreacted
PAM. Reaction conditions were [PAM]/[phosphate]= 0.37, 37C, in pH 7 20 mM
phosphate buffer with .0.15 M NaCI. Unreacted drug was removed 24 minutes after
initiation of the reaction. Curve is % crosslinking = Ae~kt + b where A=20.5, k=0.00382,
and b= 21.8. Half-life for crosslinks is about 181 minutes (3 hours). DNA MW=9.7 x
107. Buffer was 20 mM pH 7 sodium phosphate with 0.15 M NaCI. MK1-131.
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HN2
Figures 5-3 and 5-4 show crosslinking profiles forHN2-DNA reaction mixtures in
which unreacted drug was removed at 5.5 minutes into the reaction. Features of note are
the half-life of about 50 to 65 minutes (1 hour) (r2 values were 0.925 and 0.986) and a
small fraction of crosslinks that seem to resist decay or which decay on amuch longer time
scale. Another feature of interest is the lack of additional crosslink formation after
unreacted drug has been removed.
HN2 was also used in the PM2 closed circularDNA assay for strand breaks. PM2
DNA that was treated withHN2 for 17 hours showed no increase in Fioo m the ethidium
bromide assay solution.
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Loss of HN2 Crosslinks After Removal of Unreacted Drug, Trial 1
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Figure 5-3 Loss of Crosslinking from Reaction Mixture after Removal ofUnreacted
HN2, Trial 1. Reaction conditions were [HN2]/[phosphate]= 0.37, 37C, in pH 7 20 mM
phosphate buffer with .0.15 M NaCI. Unreacted drug was removed 5.5 minutes after
initiation of the reaction. Curve is % crosslinking = Ae'^1 + b where A=19.5, k=0.01 13,
and b= 8.09. Half-life for crosslinks is about 62 minutes (1 hour). DNA MW=9.7 x 107.
Buffer was 20 mM pH 7 sodium phosphate with 0.15 M NaCI. MK1-74.
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Loss of HN2 Crosslinks After Removal of Unreacted Drug, Trial 2
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Figure 5-4 Loss of Crosslinking from ReactionMixture after Removal ofUnreacted
HN2, Trial 2. Reaction conditions were [HN2]/[phosphate]= 0.37, 37C, in pH 7 20 mM
phosphate bufferwith .0.15 M NaCI. Unreacted drug was removed 5.5 minutes after
initiation of the reaction. Curve is % crosslinking = Ae"kt + b where A=36.6, k=0.0130,
and b= 5.22. Half-life is about 53 minutes (0.9 hour). DNA MW=9.7 x 107. Buffer was
20 mM pH 7 sodium phosphate with 0.15 M NaCI. MK1-88.
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Discussion
No Lag Time Seen for Crosslinking Step
One surprising result for both PAM and HN2 is that the delay between
monoalkylation and crosslinking which was expected for both drugs but which was
expected to be especially long for PAM was not seen at all. There was no increase in the
percent crosslinking after removal of unreacted drug for either PAM orHN2. Previous
chapters have shown that PAM andHN2 have virtually identical solution stabilities, that
they have very similar activation energies, and that they have the same maximum extent of
crosslinking. The only major difference has been the steric factor of the Arrhenius equation
wherebyHN2 would be expected to react faster than PAM with its bulky phenyl group.
However, computer molecular modelling studies have shown that PAM's steric problems
should not interfer with monoalkylation (C. G. Reinhardt, unpublished results). Thus the
steric differences between PAM and HN2 would have to affect the crosslinking step with
PAM having a much longer lag between monoalkylation and crosslinking than HN2 has.
Other studies have shown a lag betweenmonoalkylation and crosslinking for PAM.
One such study by D'lncalci et al (1985) used amodification of the alkaline elution
technique. DNA from cells (an SV-40-transformed human embryonic cell line) that had
been exposed to PAM and washed to remove unreacted PAM was allowed to incubate on
filters for various times before elution. PAM showed an increase in crosslinking over time
even though no free drug was present, indicating thatmonoalkylated sites were slowly
converted to crosslinks.
However, our results did not show a lag time for either drug. If such a lag time does
exist, our method may be missing it . Perhaps our assumption that both monoalkylation
and crosslinking are arrested when an aliquot
from the reaction is placed in the alkaline
ethidium bromide assay solution is incorrect. Subsequent studies (C.G. Reinhardt,
unpublished data) have shown that the PAM crosslinking step does occur in the alkaline
ethidium bromide assay once monoalkylation has occurred at a neutral pH
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Unimolecular Decay
The decay plots for both PAM andHN2 DNA interstrand crosslinks exhibit the
qualities of unimolecular decay. In addition to the fact that the plots fit well into an
exponential decay curve, the half-life seems to be independent of the amount of
crosslinking present at the beginning of the decay curve, at least for HN2. In Figure 5-3
the initial amount ofHN2 DNA interstrand crosslinking was only about 27% in contrast to
the 37% initial crosslinking by HN2 in Figure 5-4, yet the half-lives were essentially the
same (62 versus 53 minutes). Furthermore, the half-life ofDNA interstrand crosslinking
produced by PAM andHN2 is also independent of the molecular weight, (results not
shown, R. Gruszca, unpublished data)
For both PAM andHN2, the true half-lives reported in Chapter 5 are consistent with
the apparent half lives in the profiles in Chapter 1. The true half-lives determined here were
expected to be shorter than the apparent half lives since removal of unreacted drug early in
the reaction should prevent the initiation of new crosslinks while the established crosslinks
are lost. Both PAM's and HN2's true half-lives are about 15% as long as the apparent half
lives, though there is more uncertainty in this estimate for PAM since both the apparent and
true half lives ofPAM showed larger variation than did the same values forHN2.
Decay-Resistant Crosslinks
PAM and HN2 both exhibited a significant fraction of crosslinks that seem to be
decay-resistant. ForHN2, 14 to 29% of the crosslinks that had formed at the time of
separation of unreacted drug remained as a decay-resistant fraction. For PAM, over half of
the crosslinks present at the time of separation of unreacted drug resisted decay. Some
portion of the resistant fraction may be an artifact of the procedure. Specifically, over the
course of the reaction, evaporation may increase the reaction solution concentration and
hence artificially elevate both FlOO and Fd- To guard against this, the reaction vessel was
kept tightly capped except when an aliquot was removed. FlOO values did not increase
significantly over time. To further test the importance of evaporation, the control samples
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should be subjected to the same long-term heating regimen. This has not yet been carried
out Although many previous studies have shown that PAM (Parsons, 1984 andMurnane
and Byfield, 1977) and HN2 (Ewig and Kohn, 1977 and Ojwang et al , 1989) can produce
decay-resistant or long-lived crosslinks under certain conditions, the present results are
surprising in light of the apparent linearity of the Arrhenius plots in Chapter 4. This was
interpreted to mean that each drug reacts with a unique site inDNA or with several sites
having similar activation energies. Here there seem to be two populations of crosslinks for
each drug, a population which loses crosslinks easily with the half lives indicated above
and a second population in which crosslinks are more stable.
It is possible that the drugs crosslinked at two different sites with similar activation
energies. A second possibility is that the drugs crosslink at two sites with different
activation energies but the relative populations of the sites and their relative activation
energies are such thatwe cannot detect the departure from linearity that would be expected
in the Arrhenius plots. If either of these explanations are correct, then one would expect
the magnitude of the decay-resistant fraction to vary with the extent of crosslinking at the
time of separation of unreacted drug. This seems to be the case with HN2. In Figure 5-3,
the extent of crosslinking at the time of separation of unreacted drug was 27%, and 29% of
the initial crosslinks resisted decay. But in Figure 5-4 with 37% crosslinking at separation,
only 14% of the initial crosslinks resisted decay. Further studies are neededwith both
PAM and HN2 to explore the dependence of the size of the decay-resistant population of
crosslinks on the extent of crosslinking at the time of separation of unreacted drug.
A third possibility is that there is only one crosslinking site but processes compete to
either stabilize or destabilize the crosslink once it is established. If this is the case, then the
fraction of decay-resistant crosslinks should be independent of the extent of crosslinking at
the time of separation of unreacted drug for a given temperature and pH, butmight change
if the pH and temperature are varied. This possibility will be discussed later in light of the
literature. Whatever the explanation for the two populations of crosslinks with different
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stabilities, it is clear that PAM produces a higher fraction of decay-resistant crosslinks.
This is likely to be an important factor in PAM's greater clinical effectiveness since more
long-lived crosslinks increase the chance that a crosslink will be present to interfer at the
time ofDNA replication in the cancer cell.
Is the Apparent Loss of Crosslinking an Artifact of Nicking?
One concern in both our alkaline ethidium bromide assay for crosslinked DNA and
the alkaline elutionmethod has always been thatDNA strand scission produced by either
the drugs or the alkaline solutions would cause artificially low values for crosslinking.
This is due to the fact that Fd does not measure the amount of crosslinking directly but uses
the amount of denaturation-resistant duplex DNA as an indirectmeasure of the amount of
crosslinking. If nicking occurs in vivo, the DNA strands are not separated or lost and the
lesion is probably repaired. The actual crosslink probably remains and probably interfers
withDNA replication. But in our assay system with alkaline heat denturation, a nick in
DNA's sugar-phosohate backbone could lead to the loss of duplex DNA and thus an
apparent loss of crosslinks even though the crosslink itself is intact. This possibility is
illustrated in Figure 5-5.
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Nicking of DNA Backbone and Loss of Denaturation-Resistant Duplex DNA
_ _ _x_
DNA with crosslink.
Fluorescence is the
same with orwithout
denaturation.
DNA with backbone
nick. Not denatured.
Fluorescence is the
same as in a).
DNA with backbone
nick. Denatured.
Fluorescence is anninished
due to partial loss of duplex
DNA. Crosslink is intact
Figure 5-5 Nicking ofDNA Backbone and Loss ofDenaturation-Resistant Duplex DNA
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Some studies have indicated that such strand scission occurs. For example, Ludlum
(1967) reported that nitrogen mustard causes degradation of poly(A) and poly(U) which is
reflected in decreased molecularweight and viscosity. The degradation was complete
within 12 hours. However, this study may not be directly applicable to our experiments or
to the situation in clinical use. Guanine residues seem to be the preferred sites of alkylation
by HN2 inDNA, so studies of poly(A) and poly(U) may be irrelevant. In addition,
poly(A) and poly(U) are single-stranded, and normal duplex DNA might behave differently
in that the crosslink in a duplex may be more stable than an alkylation in a single-strand.
Our experiment in which PM2 supercoiled closed circularDNA was exposed toHN2
and to the alkaline ethidium bromide assay solution without a change in the Fioo values
indicates that our apparent loss of crosslinking is true loss of crosslinks and not an artifact
of the experimental method. Kohn's (1978) and Hanssen's (1987) teams also had
evidence that strand breaks do not occur in the time frame of interest in the alkaline elution
method they used to produce their reaction profiles (see Figures 1-1 and 1-2). Other
studies that indicate that strand breaks occur describe it as an extremely slow process.
Lindahl andAndersson (1972) measured the production of single-strand breaks at apurinic
sites using a sedimentation velocity technique and found that an average DNA strand lasted
about 190 hours at pH 7.4 and 37C before cleaving at an apurinc site. This is much
longer than the half-life we found for HN2 crosslinks, so it is highly unlikely that strand
scission accounts for the decline in Fden over time. As a result, we can turn our attention to
ways by which the actual crosslinks may be lost and to the differences there may be
between PAM and HN2 in those processes.
Depurination versus Opening and the Fate of DNA Interstrand Crosslinks
Given that strand scission is too slow to affect cross-linked DNA in the time frame of
our experiments, two processes which may compete to affect crosslinks are depurination
and imidazole ring opening. Figure 5-6 shows proposedmechanisms
for the two
processes. Imidazole ring opening is base-catalyzed and depurination is acid-catalyzed, but
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it is conceivable that both processes occur to some extent in cells and in our neutral reaction
mixture.
The effects of the two processes on crosslinks are quite different. As shown in
Figure 5-7, imidazole ring opening stabilizes the crosslink by removing the strain guanine
experiences in the crosslink. Specifically, Hausheer et al (1989) have shown through
advanced molecular computationalmethods that ring opening with phosphoramide mustard
provides addtional degrees of conformational freedom which reduces the helical distortion.
DNA containing a ring-opened, crosslinked guanine residue will continue to renature after
heating in base since the strands are still in register. DNA which was crosslinked but
experiences depurination at the crosslink site will no longer renature after heating in base
since the strands are not held in register.
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Mechanisms for Imidazole Ring Opening and Depurination
j? CH,-H
CM,-* 0*yr H,N^N
[ |J JH.CHO
H,N
O CH,R
HO OH
XJG
HOVV
R = \ AOH
HO' SjH
Fie. 3.
R:CH H,CH,OH, CH,CI, CH,F, CH,NH,. CH,-N'-guanosin
Figure 5-6 Figure 3 from MUller and Eisenbrand (1985)
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The Effects on DNA of the Competing Processes of Imidazole Ring
Opening and Depurination
Strain is relieved
and crosslink is
stabilized.
E
CH
Ring Opening
H+
Depurination
DP Crosslink is lost.
DNA no longer
resists denaturation.
+ x-pur
Figure 5-7 Imidazole Ring Opening versus Depurination
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It seems a strong possibility that these two competing processes account for the
decay-sensative and decay-resistant populations of crosslinked DNA observed in our
experiments. Crosslinks acted upon by the depurination process would be the population
with the relatively short half-lives shown above. Crosslinks acted upon by ring opening
would be the population that is resisting decay or decaying on amuch longer time scale. It
also seems likely that PAM andHN2 crosslinks have different susceptibilities to these
competing processes which would account for PAM's larger fraction of decay-resistant
crosslinks.
Kallama andHemminki (1986) have studied the rates of depurination, ring-opening,
and overall disappearance ofprimary products of the reaction ofHN2 with
deoxyguanosine. It may be of interest to examine their results, though with caution since
isolated alkylated bases may not react the same as the same alkylated bases in DNA. At
27C and pH 7.4, the primary product of the reaction ofHN2 and deoxyguanosine
disappeared with an overall half life of 0.65 hours, very close to our half life of about 1
hour for the disappearance ofHN2 DNA interstrand crosslinks. They reported a half life
of 3.6 hours for ring opening at 25C and pH 8.5 and a half life for depurination of 1.6
hours at 25C and pH 4.2. All half lives were measured using HPLC. At first glance,
comparison of the half lives for depurination and ring opening seems impossible because of
the different pHs, but the pHs used were the optima for the reactions.. Thus ring opening
seems to be slow forHN2 compared to depurination. This could explain why HN2 has a
relatively small fraction of decay-resistant crosslinks. It would be most informative to have
data for PAM's half lives for depurination and ring-opening under the same condtions.
Miiller and Eisenbrand (1985) studied the effects of different alkylating agents at
guanosine N-7 on the rates of depurination and ring-opening. First they found an inverse
linear relationship between pKa and
c* (Taft constant, a measure of inductive electron-
withdrawing effects) for the substituents. Next, they measured the dependence of the rates
of depurination and ring opening on the
a* of the substituents. For both reactions, the rate
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was faster for higher values of a*, but the effectwas slight for depurination and dramatic
for ring opening. Thus crosslink-stabilizing ring-opening would predominate over
crosslink-losing depurination for a higher a* substituent. It would be very useful to know
a* for PAM andHN2 since a higher value of o* for PAM would then account for PAM's
greater fraction of decay-resistent crosslinks. Unfortunately, this information does not
appear to be available, but it could form the basis for future studies.
One study could be performed using amodification of our technique to evaluate this
model, even without knowing Taft constants for PAM andHN2. If a separation reaction is
run at a slightly acidic pH (perhaps 5 or 6), depurination should be accelerated compared to
ring opening and the fraction decay-resistant crosslinks should decrease. On the other
hand, if a separation reaction is run at a slightly basic pH (maybe 8 or 9), ring-opening
should be favored more and the fraction of decay-resistant crosslinks should increase.
These reactions should be run for both PAM and HN2.
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Summary
DNA interstrand crosslinks produced by PAM and HN2 decay with intrinsic half
lives of 3 hours and 1 hour, respectively. A fraction of crosslinks produced by each drug
resists decomposition or decay at amuch slower rate, and PAM produces a larger fraction
of decay-resistant crosslinks. The hypothesis that PAM has a long lag time between
monoalkylation and crosslinking was not supported.
Possible explanations for the marked differences between the behaviors ofPAM and
HN2 crosslinks were explored. Future research should focus on how the two drugs might
produce different relative amounts of crosslink-stabilizing ring opening and crosslink-
destroying depurination. In addition, other nitrogen mustards such as uracil mustard and
phosphamide mustard should be investigated using the techniques of this and the previous
four chapters to further investigate the mechanism of action of the nitrogen mustard class of
chemotherapeutic agents.
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